{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:57Z","timestamp":1792037097535,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.ajkd.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T23:08:38Z","timestamp":1752880118000},"page":"510-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tenapanor: An Update on Evidence of Effectiveness and Guidance on Practical Use"],"prefix":"10.1053","volume":"86","author":[{"given":"Ian","family":"Da Silva Lugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1134","authenticated-orcid":false,"given":"Jaime","family":"Uribarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2025.06.008_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cca.2017.09.005","article-title":"Phosphate and mortality risk in end-stage renal disease: a meta-analysis","volume":"474","author":"Hou","year":"2017","journal-title":"Clin Chim Acta"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.008_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114678","article-title":"Mineral metabolism markers are associated with myocardial infarction and hemorrhagic stroke but not ischemic stroke in hemodialysis patients: a longitudinal study","volume":"9","author":"Tagawa","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.008_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12882-022-02918-0","article-title":"Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients","volume":"23","author":"Jung","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2025.06.008_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2020.11.020","article-title":"Association of hyperphosphatemia with an increased risk of sudden death in patients on hemodialysis: ten-year outcomes of the Q-cohort study","volume":"316","author":"Hiyamuta","year":"2021","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.008_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/ndt\/gfad190","article-title":"Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients","volume":"39","author":"Barrera-Baena","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"10.1053\/j.ajkd.2025.06.008_bib6","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.008_bib7","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1053\/j.ajkd.2018.11.004","article-title":"Dietary phosphate and the forgotten kidney patient: a critical need for FDA regulatory action","volume":"73","author":"Calvo","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.008_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","article-title":"KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-Mineral and Bone Disorder (CKD-MBD)","volume":"55","author":"Uhlig","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"3 suppl 1","key":"10.1053\/j.ajkd.2025.06.008_bib9","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.12.001","article-title":"US Renal Data System 2022 annual data report: epidemiology of kidney disease in the United States","volume":"81","author":"Johansen","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.008_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.ajkd.2020.05.025","article-title":"State-of-the-art management of hyperphosphatemia in patients with CKD: An NKF-KDOQI controversies perspective","volume":"77","author":"Scialla","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.06.008_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/sdi.12568","article-title":"Phosphate binders and targets over decades: do we have it right now?","volume":"30","author":"Marcuccilli","year":"2017","journal-title":"Semin Dial"},{"issue":"6","key":"10.1053\/j.ajkd.2025.06.008_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/sdi.12416","article-title":"Phosphate binders and clinical outcomes in patients with stage 5D chronic kidney disease","volume":"28","author":"Zoccali","year":"2015","journal-title":"Semin Dial"},{"issue":"11","key":"10.1053\/j.ajkd.2025.06.008_bib14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40265-017-0758-5","article-title":"A review of phosphate binders in chronic kidney disease: Incremental progress or just higher costs?","volume":"77","author":"St. Peter","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1053\/j.ajkd.2025.06.008_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156891","article-title":"Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"11","author":"Sekercioglu","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1053\/j.ajkd.2025.06.008_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/14740338.2022.2044472","article-title":"An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles","volume":"21","author":"Ogata","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"456","key":"10.1053\/j.ajkd.2025.06.008_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6474","article-title":"Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability","volume":"10","author":"King","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.06.008_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1159\/000516156","article-title":"Therapeutic effects of add-on tenapanor for hemodialysis patients with refractory hyperphosphatemia","volume":"52","author":"Shigematsu","year":"2021","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.06.008_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10157-023-02406-1","article-title":"Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial","volume":"28","author":"Nakayama","year":"2023","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.06.008_bib21","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.008_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45080-9","article-title":"Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia","volume":"13","author":"Koiwa","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1053\/j.ajkd.2025.06.008_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2410389","article-title":"Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis","volume":"46","author":"Yu","year":"2024","journal-title":"Ren Fail"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.008_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.ajkd.2023.03.019","article-title":"Tenapanor for the treatment of hyperphosphatemia in Japanese hemodialysis patients: a randomized phase 3 monotherapy study with an up-titration regimen","volume":"82","author":"Fukagawa","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.008_bib25","first-page":"479","article-title":"Safety and efficacy of tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized phase 3 trial (PHREEDOM)","volume":"182","author":"Block","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1053\/j.ajkd.2025.06.008_bib26","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.34067\/KID.0000000000000280","article-title":"Tenapanor improves long-term control of hyperphosphatemia in patients receiving maintenance dialysis: the NORMALIZE Study","volume":"4","author":"Silva","year":"2023","journal-title":"Kidney360"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.008_bib27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.34067\/KID.0000000000000387","article-title":"Tenapanor as therapy for hyperphosphatemia in maintenance dialysis patients: results from the OPTIMIZE study","volume":"5","author":"Sprague","year":"2024","journal-title":"Kidney360"},{"issue":"9","key":"10.1053\/j.ajkd.2025.06.008_bib28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2215\/CJN.09050815","article-title":"Effect of tenapanor on interdialytic weight gain in patients on hemodialysis","volume":"11","author":"Block","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.008_bib29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ndt\/14.5.1195","article-title":"Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine","volume":"14","author":"Katai","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.008_bib30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.008_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010117","article-title":"Nicotinic acid and related compounds: a meta-analysis of their use for hyperphosphatemia in dialysis patients","volume":"97","author":"Liu","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.008_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ndt\/gfac206","article-title":"Modified-release nicotinamide for the treatment of hyperphosphatemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial","volume":"38","author":"Ketteler","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"41","key":"10.1053\/j.ajkd.2025.06.008_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012731","article-title":"Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625009370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625009370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:49:35Z","timestamp":1758577775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625009370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0272638625009370"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.06.008","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenapanor: An Update on Evidence of Effectiveness and Guidance on Practical Use","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}